New cancer drug enters first human safety tests
NCT ID NCT07205198
Summary
This is a first-in-human study to test the safety and side effects of an experimental drug called SIBP-A10 in people with advanced cancers that have spread. Researchers will give increasing doses to up to 160 participants to find the highest dose that is safe and tolerable. The main goal is to understand how the body handles the drug and to identify a recommended dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Affiliated to Dalian University
RECRUITINGDalian, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.